Open Access. Powered by Scholars. Published by Universities.®
Pharmacoeconomics and Pharmaceutical Economics Commons™
Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Antidepressants (1)
- Autoimmune diseases (1)
- Chronic non-cancer pain conditions (1)
- Healthcare costs (1)
- Healthcare expenditures (1)
-
- Healthcare resource utilization (1)
- Immune checkpoint inhibitors (1)
- Long-term opioid therapy (1)
- Machine learning (1)
- Major depressive disorder (1)
- Melanoma (1)
- Metastatic melanoma (1)
- Multimorbidity (1)
- Older patients (1)
- Pain medications (1)
- Predictors (1)
- SEER Medicare (1)
- Treatment-resistant depression (1)
Articles 1 - 2 of 2
Full-Text Articles in Pharmacoeconomics and Pharmaceutical Economics
Multimorbidity, Immune Checkpoint Inhibitor Use, And Healthcare Expenditures Among Older Patients With Late-Stage Melanoma, Pragya Rai
Graduate Theses, Dissertations, and Problem Reports
With decades of unchanged cancer care with no added survival benefit, immune checkpoint inhibitors (ICI) changed the treatment landscape of late-stage melanoma in 2011. A key factor in determining the use of ICIs is the presence of pre-existing chronic conditions, which can influence the outcome. However, the prevalence of multimorbidity (defined as presence of two or more chronic conditions) among older patients with late-stage melanoma remains unknown. It also remains unknown if the presence of multimorbidity factors into the use of ICIs. Hospital-related factors associated with ICI use have been studied. Yet, patient-level factors, such as age, sex, marital status, …
Predictors And Health Outcomes Of Treatment-Resistant Depression Among Adults With Chronic Non-Cancer Pain Conditions And Major Depressive Disorder, Drishti Shah
Graduate Theses, Dissertations, and Problem Reports
Understanding major depressive disorder (MDD) as a comorbidity in patients with chronic non-cancer pain conditions (CNPC) is of importance because of the high prevalence and well documented bi-directional relationship between MDD and pain. Furthermore, presence of CNPC among adults with MDD often reduces benefits of antidepressant therapy, thereby increasing the possibility of treatment resistance. Treatment-resistant depression (TRD) commonly defined as insufficient response to multiple antidepressant trials, often worsens depression and pain symptoms and can amplify the clinical and economic burden among adults with CNPC and MDD. Additionally, long-term opioid therapy (LTOT) may be prescribed at a higher rate to adults …